58 (PB046): Tumor-agnostic Efficacy and Safety of Lirafugratinib, a Highly Selective FGFR2 Inhibitor, in Patients (pts) with Advanced Solid Tumors with FGFR2 Fusions or Rearrangements (f/r): the ReFocus Study

A. Hollebecque,E. Dotan, C.Y.A. Liao,D. Roda, E. Fontana,H. Babiker, R.D. Kim, D.Y. Oh, F. Ghiringhelli, I. Moreno, J. Liu, V. Subbiah, A. Varkaris, M.J. Borad,P.A. Cassier, A. Deary, F.T. Ramirez, F. Ricard, K.Y. Jen,A.M. Schram

European Journal of Cancer（2024）

引用 0|浏览1